tracon
pharmaceuticals
present
wainwright
annual
global
investment
conference
san
diego
globe
newswire
tracon
pharmaceuticals
nasdaq
tcon
clinical
stage
biopharmaceutical
company
focused
development
commercialization
novel
targeted
cancer
therapeutics
utilizing
cost
efficient
product
development
platform
partner
companies
develop
commercialize
innovative
products
announced
today
charles
theuer
president
ceo
present
corporate
overview
wainwright
annual
global
investment
conference
wednesday
september
pm
edt
access
live
webcast
presentation
please
visit
events
presentations
page
within
investors
section
tracon
pharmaceuticals
website
replay
webcast
also
available
following
event
tracon
tracon
develops
targeted
therapies
cancer
utilizing
capital
efficient
cro
independent
product
development
platform
company
pipeline
includes
envafolimab
subcutaneous
antibody
developed
treatment
sarcoma
goal
initiating
registrational
trial
fourth
quarter
small
molecule
drug
candidate
treatment
prostate
cancer
phase
small
molecule
drug
candidate
developed
treatment
lung
cancer
antibody
phase
development
treatment
advanced
solid
tumors
tracon
actively
seeking
additional
corporate
partnerships
whereby
leads
regulatory
clinical
development
shares
cost
risk
clinical
development
leads
commercialization
partnerships
tracon
believes
serve
solution
companies
without
clinical
commercial
capabilities
learn
tracon
product
pipeline
visit
tracon
website
